Oral Presentations 4 Pharmacogenetics

17:00 • 641 • DPYD Genotype-Guided Dose Reduction Alone Is Insufficient for Exposure Optimization: Real-World Evidence Supporting Systematic 5-FU TDM > A. Alan Fotoohi 17:13 • 515 • Comprehensive DPYD sequencing uncovers rare variants linked to severe toxicities in fluoropyrimidine-treated patients > J. Jeanne Petit 17:26 • 403 • The INTEGRATE Study: Integrated Pharmacogenetics, TDM and Active Pharmacovigilance as Innovative Tools for the Optimisation and Appropriateness of Drug Therapy > B. Bianca Posocco 17:39 • 156 • Severe toxicity risk of UGT1A1 intermediate metaboliser genotype and other baseline characteristics in patients treated with irinotecan-containing chemotherapy > S. Sofía Peeters 17:52 • 133 • 6-Mercaptopurine metabolics profiles and Clinical outcome in TPMT and NUDT15 phenotype during maintenance therapy for paediatric acute lymphoblastic leukaemia > A. Apichaya Puangpetch 18:05 • 663 • Do Phenotypic Tacrolimus Dose Requirements Align with Genotypic Metabolizer Classification in Renal Transplant Recipients? > D. Dipan Tapader 18:18 • 731 • Drug–drug–gene interactions as risk factors for statin- and ezetimibe-associated hepatotoxicity: a pharmacogenomic case series > L. Livija Šimicevic